Schizophrenia is a complex disabling mental disorder, and many patients present poor response to available treatments. Accumulating evidence about the role of the glutamate/nitric oxide pathway in mediating the positive and negative symptoms of schizophrenia suggests potential benefits of drugs that modulate this system. The aim of this study was to test the efficacy of isosorbide mononitrate (ISMN) as an adjunctive therapy for symptomatic outpatients with schizophrenia.

中文翻译：

---

单硝酸异山梨醇作为精神分裂症的辅助治疗：一项随机对照交叉试验。

精神分裂症是一种复杂的致残精神障碍，许多患者对现有治疗反应不佳。关于谷氨酸盐/一氧化氮途径在调节精神分裂症阳性和阴性症状方面作用的越来越多的证据表明，调节该系统的药物具有潜在的益处。本研究的目的是测试单硝酸异山梨酯 (ISMN) 作为有症状的门诊精神分裂症患者的辅助疗法的疗效。